daclizumab + mycophenolate mofetil + sirolimus

This is a combination immunosuppressive regimen consisting of **daclizumab**, a humanized monoclonal antibody targeting the alpha subunit of the interleukin-2 receptor (CD25); **mycophenolate mofetil**, an antimetabolite prodrug that inhibits the enzyme inosine monophosphate dehydrogenase, thereby suppressing lymphocyte proliferation; and **sirolimus**, a mammalian target of rapamycin (mTOR) inhibitor that also reduces T-cell proliferation by blocking IL-2 signal transduction. This combination has been used as a **calcineurin inhibitor-sparing regimen** for the prevention of acute rejection in organ transplant recipients, particularly those with delayed or impaired graft function, and is associated with effective immunosuppression with a distinctive side-effect profile. Primary indications include prevention of acute rejection in kidney and heart transplantation[1][5].